Author

Beatrice Suero

Observed names: B Suero, B. Suero

Institution: EVERSANA (Canada)

Observed institution: EVERSANA (Canada)

ORCID: 0009-0009-3134-5136

Observed ORCID: 0009-0009-3134-5136

OpenAlex ID: A5001617887

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

2024 · Ernest Nadal, Nada Rifi, et al. · Lung Cancer · 16

Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review

2025 · Shaji Kumar, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 12

P-282 Ranking importance of prognostic factors for relapsed/refractory multiple myeloma (RRMM): international physician panel consensus following a systematic review of the literature

2023 · Shaji Kumar, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 3

Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy

2021 · Clara Chen, Gerwin A. Huls, et al. · Blood · 2

A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data

2026 · Alexander Breskin, Mostafa Shokoohi, et al. · Annals of Hematology · 1

Efficacy of Inebilizumab in N‐ MOmentum Trial Participants With or Without Prior Immunosuppressants

2026 · Bruce A. C. Cree, Beatrice Suero, et al. · Annals of Clinical and Translational Neurology

Abstract PS5-04-02: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-positive metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program

2026 · C. Brezden-Masley, S. Shokar, et al. · Clinical Cancer Research

Abstract PS2-06-08: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-low metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program

2026 · C. Brezden-Masley, S. Shokar, et al. · Clinical Cancer Research

MSR36 Methods for Handling Non-Proportional Hazards in Economic Modeling

2025 · Beatrice Suero, Roya Gavanji · Value in Health

MSR3 Parametric Model Selection: Beyond AIC/BIC in Health Economic Context

2025 · Beatrice Suero, Roya Gavanji · Value in Health

P.009 Long-term comparative efficacy of inebilizumab from N-MOmentum participants versus azathioprine and immunosuppressants and placebo in NMOSD patients

2024 · B Cree, B Suero, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Long-term Comparative Efficacy of Inebilizumab in the AQP4+ Subpopulation from N-MOmentum Open-label Period Versus Azathioprine and Immunosuppressants and Versus Placebo in Patients with NMOSD (S32.001)

2024 · Bruce Cree, Beatrice Suero, et al. · Neurology

POSB364 Systematic Literature Reviews (SLRS) of Economic Evaluations and Health Utility Studies of AML Treatments for Adults Receiving High Intensity Induction Therapy, with or without Maintenance Therapy

2022 · M Ahmed, B Suero, et al. · Value in Health

Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

2020 · Clara Chen, Tim Disher, et al. · Blood

Works count: 14

Citation count: 34

H-index: 3

I10-index: 2